Investment Analysis Report: TLRY (en)

This report is auto-generated by an educational research tool for learning purposes only. The content is for general information and educational reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. **# [Qiltrack AI] Tilray Brands Inc (TLRY) 3-Minute Overview** --- ### 🎯 First Layer: 30-Second Takeaway **💡 In one sentence** Tilray is basically a high‑beta cannabis and consumer brands play that’s still losing a lot of money, but whose stock is now trading at “distressed” valuation levels and swinging wildly with U.S. legalization news. **📍 Basic snapshot** Market cap **~$1.06B** · Cannabis / Pharmaceuticals · **NASDAQ** · Share price **$9.18** --- **⚡ Three things you really should know** 1. **⚠️ Deep in the red despite okay gross margins** Gross margin is around **29%**, which is decent for a consumer/cannabis player, but net margin is an extreme **-259%** and ROE is about **-93%** → the core issue is not demand, it’s that the cost structure and write‑offs are crushing shareholders. 2. **📉 Growth has slowed while dilution risk is real** 5‑year revenue CAGR is a solid **~31%**, but the last 3‑year CAGR has already slowed to **~9%**, and recent articles highlight **cash burn, share dilution, and a 1:10 reverse split** → management is trying to buy time, but equity holders are taking the pain. 3. **🎰 “Option on legalization” more than a fundamentals story** The stock jumped **~40%** on news about Trump‑era federal cannabis rescheduling and trades with a **beta ≈ 2.0**, plus it’s sitting in the **lower third** of its 52‑week range with **P/S ~1.3x and P/B ~0.28x** → pricing is low, but the investment case is heavily tied to regulatory upside, not current earnings quality. --- **🎯 Quick health check** | Dimension | Rating | Detail | |-----------------|------------------------|--------| | Profitability | Weak👎 | Net margin **-258%**, ROE **-93%** – very loss‑making. | | Growth | Slow 📉 / Mixed | Revenue 5Y growth **31%** → 3Y **9%** – clear deceleration. | | Financial health| Average💛 | Low leverage (D/E **0.20**), current ratio **2.6**, but cash flow per share **-2.01**. | | Valuation | Apparently cheap | **No PE (loss‑making)**, **P/S ~1.3x**, **P/B ~0.28x**, price near lower third of 52‑week range. | --- ### 📋 Second Layer: Understand It in 2 Minutes #### 📊 How does this company make money? **Business model in one line:** Sells cannabis and related consumer products, mainly in North America and internationally, trying to scale brands and distribution while waiting for regulatory tailwinds (especially in the U.S.). **Revenue breakdown:** (Detailed segment data is not in the dataset, but based on news flow, the mix likely includes cannabis, international medical/recreational, and beverage/craft brands. Exact percentages: **[data not available]**.) | Segment (high level) | Share | Trend | Comment | |-----------------------------|-------|-------|---------| | Cannabis (medical/rec) | [n/a] | ↑ | Core strategic focus; highly sensitive to legal changes. | | Beverages / craft & others | [n/a] | →/↑ | Diversification, but not yet offsetting cannabis volatility. | **Efficiency: can it turn sales into profits?** | Metric | Value | Level | Interpretation | |-------------------|----------------|------------------|----------------| | Gross margin TTM | **28.7%** | Moderate | The product economics aren’t terrible; the problem is below gross profit. | | Operating margin | **-270%** | Extremely weak | Heavy operating costs, impairments, and/or restructuring hitting the P&L hard. | | Net margin TTM | **-258.5%** | Extremely weak | Every $1 of sales is turning into >$2.5 of loss – not sustainable. | | ROE TTM | **-92.8%** | Very poor | Equity is being eroded; this is classic “value‑trap risk” unless things turn fast. | --- #### 📈 How is growth? **Growth profile:** **Slowing / uneven growth with poor earnings quality** | Indicator | Latest info | vs earlier | Trend judgment | |--------------------|-------------------------|-----------|----------------| | Revenue growth 5Y | **~31.3% CAGR** | — | Fast historically (sector boom phase). | | Revenue growth 3Y | **~9.3% CAGR** | ↓ vs 5Y | Clear deceleration. | | EPS growth | **[data not available]** (negative EPS) | — | Losses make “growth” less meaningful. | **Growth quality – what’s really going on?** - Top‑line is still growing, but the **trend is slowing** as the early cannabis boom cools and competition/regulation bite. - The company is **not converting growth into profit or cash**: cash flow per share TTM is **-2.01**, and interest coverage is **-47.4** (losses even before interest are large). - Recent earnings are **very volatile** (huge negative surprises and a big one‑off loss around the reverse split period), suggesting a lot of non‑recurring items, write‑downs, or restructuring flowing through. So even where growth exists, it’s **not yet “healthy” growth** for equity holders. --- #### 💰 Is the balance sheet OK? **In one phrase:** Low leverage and decent liquidity, but **the business is burning cash**, so over time that still pressures equity. | Metric | Value | “Safe” line | Assessment | |------------------------|-------------|--------------------|------------| | Debt-to-equity | **0.20** | <0.6 usually fine | ✅ Conservative leverage. | | Long-term D/E | **0.16** | — | ✅ Not overbuilt on long-term debt. | | Current ratio | **2.62** | >1.5 healthy | ✅ Comfortable short-term liquidity. | | Quick ratio | **1.37** | >1.5 ideal | ⚠️ Slightly below ideal but not alarming. | | Interest coverage | **-47.4** | >3x preferred | 🚨 Operating losses, not “covered” at all by earnings. | | Cash flow/share TTM | **-2.01** | >0 | 🚨 Business is consuming cash. | So the **balance sheet is not the immediate problem (low debt, OK liquidity)**; the real problem is **ongoing losses and negative cash flow**, which can eventually lead to either more debt, more equity issuance (dilution), or asset sales. --- #### 🏷️ Is the stock expensive? **52-week price positioning** - 52-week low: **$3.51** - 52-week high: **$23.20** - Current: **$9.18** Position in the band: roughly **~29% up from the low**, so it’s **closer to the bottom than the top** of the yearly range. | Zone | Cheap | Fair | Expensive | |------------|------------|------------|-----------| | Range band | 0–33% | 33–66% | 66–100% | | **Current**| **● (~29%)** | | | **Valuation vs history / peers (limited by data)** | Dimension | Current | Benchmark | Comment | |----------------|-------------------|---------------------|---------| | PE TTM | **N/A (losses)** | 5Y avg: [n/a] | Earnings‑based valuation is not meaningful while loss‑making. | | P/S TTM | **~1.29x** | Industry: [n/a] | Lowish for a growth story; market isn’t paying up for topline. | | P/B | **~0.28x** | 1.0x = book value | Trading at a deep discount to its accounting equity – classic “distressed” signal. | **What is the market implicitly “betting” on?** At **P/B ~0.3x** and **no PE**, the market is basically saying: - “We don’t trust the current earnings or asset base,” **and** - “We *might* pay off if big regulatory or operational improvements materialize.” So the current price **bakes in a lot of pessimism**, and the upside case is mostly about: - U.S. federal rescheduling/legalization actually unlocking profitable growth, **and** - Management proving they can stop the cash bleed and improve margins. --- #### 📰 What’s been happening lately? | Date (approx) | Event | Impact | |---------------|-------|--------| | Jan 2026 | **Q2 2026 earnings call** | Mixed: company discussing path toward sustainable earnings and cash discipline, but numbers still choppy. | | Late 2025 | **Shares jump ~40% on reports of Trump administration easing federal marijuana restrictions** | **Bullish** – shows how leveraged TLRY is to U.S. policy headlines. | | Late 2025 | **Cannabis rescheduling to Schedule III, 1:10 reverse split** | **Mixed** – policy news positive for sector; reverse split highlights past share price erosion and dilution. | | Late 2025 | **Articles: “Tilray Brands: High-risk cannabis bet” / “Still not worth buying”** | **Bearish tone** – concerns over cash burn, dilution, and valuation vs fundamentals. | | Early 2026 | **“International Cannabis Expansion Gives Tilray Positive 2026 Outlook”** | **Cautiously positive** – suggests international growth could help, but execution risk remains. | --- ### 📊 Third Layer: Deeper Dive in ~3 Minutes #### 1. Detailed profitability snapshot (Only latest‑period data is available in the dataset.) **Profitability trends (limited view)** | Metric | “This year” (TTM) | Last year | 2Y ago | 3Y trend | |----------------|-------------------|-----------|--------|----------| | Gross margin | **28.7%** | [n/a] | [n/a] | [trend n/a] | | Net margin | **-258.5%** | [n/a] | [n/a] | Very weak level. | | ROE | **-92.8%** | [n/a] | [n/a] | Very weak level. | | Operating margin| **-270.1%** | [n/a] | [n/a] | Very weak level. | Interpretation: - The company is **operationally very far from breakeven**. - At these levels, even small negative surprises matter, because **each extra dollar of loss hits thin equity** (remember P/B 0.28x). **Growth trends (where we have data)** | Metric | Latest | 1Y ago | 2Y ago | 3Y trend | |--------------------|--------|--------|--------|----------| | Revenue growth 5Y | **31.3% CAGR** | — | — | High historically. | | Revenue growth 3Y | **9.3% CAGR** | — | — | Decelerating vs 5Y. | | EPS growth | [n/a] | [n/a] | [n/a] | EPS negative; growth not meaningful. | So Tilray has moved from **hyper‑growth narrative** toward a **slower, more mature but still unprofitable phase**. --- #### 2. Earnings track record **Last 4 reported quarters vs expectations** | Quarter end | EPS estimate | EPS actual | Surprise | |-----------------|--------------|-----------|----------| | 2025‑12‑31 | **-0.204** | **-0.41** | **-101% Miss 😟** | | 2025‑09‑30 | **-0.2295** | **0.00** | **+100% Beat 😀** | | 2025‑06‑30 | **-0.238** | **-13.00**| **-5362% Miss 😟** (massive one‑off loss) | | 2025‑03‑31 | **-0.408** | **-0.96** | **-135% Miss 😟** | **How to read this:** - There’s **one “clean” quarter** (flat EPS vs negative estimate) surrounded by **huge misses**, especially the **-13.00** print, almost certainly tied to large one‑time items (e.g., impairments, restructuring, reverse‑split accounting impacts). - For investors, this means **earnings visibility is low**; forecasting is hard, and the market will react strongly to each report. --- #### 3. Market and analyst view **Analyst recommendations (latest period: 2026‑01‑01)** Total analysts: **16** | Rating | Count | Share approx | |-----------------|-------|--------------| | Strong Buy | 3 | ~19% | | Buy | 4 | ~25% | | Hold | 8 | ~50% | | Sell | 1 | ~6% | | Strong Sell | 0 | 0% | So the **center of gravity is “Hold”**, with a non‑trivial minority willing to call it a **speculative Buy**, and very few outright Sells. (Price targets are **[data not available]**, so we can’t quantify upside/downside vs current price.) **Insiders** Recent insider activity: - 2026‑01‑07: **Steven Michael Cohen** – two transactions with code **“M”**, +12,438 shares then -12,438 shares on the same day, net **0**. - This looks like **option/RSU exercise and immediate disposition**, not a conviction buy or sell. - Net‑net, **no clear bullish or bearish insider signal** from this data. --- #### 4. Key risks you should keep in mind 1. **Business model risk – persistent losses and cash burn** - With net margin around **-258%** and negative cash flow per share, the company is far from self‑funding. - If margin improvement stalls, Tilray may need **more capital**, leading to **further dilution** or more leverage. 2. **Regulatory and political risk – cannabis remains policy‑driven** - Recent share spikes were triggered by **Trump‑era rescheduling headlines**, not by fundamentals. - Any **reversal, delay, or weaker‑than‑expected reform** in U.S. federal cannabis policy could hit the stock hard. 3. **Dilution and “reverse split” risk – shareholder value erosion** - Recent **1:10 reverse split** is a red flag: it often follows extended price declines and dilution. - Ongoing share issuance to fund losses would continue to **spread future upside over more shares**, capping per‑share value. 4. **Volatility risk – beta ~2.0** - With **beta around 2.0**, Tilray is roughly **twice as volatile** as the broader market. - This amplifies both good and bad news; position sizing matters a lot for individual investors. --- ### 🎬 Summary & Next Steps **📝 Three‑sentence wrap‑up** - **What it is:** A mid‑cap, highly volatile cannabis and consumer brands company, heavily exposed to U.S. legalization and international regulatory trends. - **Main upside:** Low headline valuation (P/B ~0.28x, P/S ~1.3x) plus potential tailwinds from cannabis rescheduling and international expansion could deliver big upside *if* management can turn growth into sustainable profits. - **Main downside:** Current operations are deeply unprofitable with negative cash flow and a history of dilution and a reverse split, so equity holders are taking sizable risk that the turnaround and regulatory catalysts may not arrive in time. --- **🔍 Want to go further from here?** - Curious whether Tilray has any real **moat** in brands, distribution, or cost structure? → Use **【Buffett Mode】** to dig into competitive advantages and durability. - Worried about hidden **balance sheet or dilution landmines**? → Use **【Muddy Mode】** to stress‑test solvency, share issuance, and worst‑case scenarios. - Thinking of it as a **high‑risk growth option on legalization**? → Use **【Musk Mode】** to model a few regulatory and margin scenarios and see what has to go right for today’s price to make sense.